secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001437749-24-008537
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech announces 1-for-15 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split at 1:15 ratio effective March 21, 2024 after market close; trading on split-adjusted basis from March 22.
- Outstanding shares reduced from ~33.4M to ~2.2M; authorized shares unchanged at 100M.
- Ticker symbol remains "MBRX" but new CUSIP 60855D309; no fractional shares, rounding up.
- Reverse split intended to cure minimum bid price deficiency for continued Nasdaq listing.
- Proportional adjustments to outstanding stock options, warrants, and equity plan shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924008537/0001437749-24-008537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924008537/mbrx20240318_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-008537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer